Physician Assistant in Cleveland, OK Accepting Medicare
3 Physician Assistant nurses found. Showing 1 - 3
 Mr. David Ward, P.A. Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 1401 W Pawnee St, Cleveland, OK 74020 Phone: 918-358-2501 |
Charles S Oleary, PAC Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 1400 W Pawnee St, Cleveland, OK 74020 Phone: 918-358-3588 Fax: 918-358-2637 |
 Vickie L Mcbee, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 1401 W Pawnee St, Cleveland, OK 74020 Phone: 918-358-2501 Fax: 918-358-9274 |
News Archive
Prolonged exposure therapy shows greater success for treating adolescent PTSD patients
Researchers at Penn Medicine report in the December 25 issue of JAMA that a modified form of prolonged exposure therapy - in which patients revisit and recount aloud their trauma-related thoughts, feelings and situations - shows greater success than supportive counseling for treating adolescent PTSD patients who have been sexually abused.
Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development
Progenics Pharmaceuticals, Inc. today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet.
Drug resistance woes hamper anti-malaria fight
Researchers have found that there is increasing resistance to the front-line treatments for malaria. A pair of studies published in The Lancet and the journal Science showed how the disease is moving fast into new territory and identified a region of the parasite's genome that may be responsible for mutating in order to survive.
VeriStrat identifies NSCLC patients likely to respond to erlotinib
A study, published in the November 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, showed the plasma test VeriStrat can predict response but not survival benefit from erlotinib. The study was conducted on a subset of patients enrolled in the NCIC Clinical Trials Group, BR.21 phase III trial of erlotinib versus placebo in previously treated advanced non-small cell lung cancer patients.
› Verified 1 days ago